REVIEW

Mycobacterium tuberculosis: drug resistance, virulence and possible solutions

About authors

1 Laboratory of Bacterial Genetics, Department of Genetics and Biotechnology,
Vavilov Institute of General Genetics of RAS, Moscow

2 Scientific Research Center for Biotechnology of Antibiotics "BIOAN", Moscow

3 Laboratory of Immunoglobulin Biosynthesis,
Mechnikov Research Institute of Vaccine and Sera, Moscow

Correspondence should be addressed: Valery N. Danilenko
Gubkina 3, Moscow, 119991; ur.ggiv@direlav

About paper

Funding: this work was supported by the Project of the Ministry of Education and Science of the Russian Federation "The role of region-specific polymorphisms of virulence genes in the formation of drug resistance of Mycobacterium tuberculosis" (Project ID RFMEFI61317X0068).

Received: 2018-06-05 Accepted: 2018-07-10 Published online: 2018-08-23
|

In spite of successful measures taken to reduce mortality associated with tuberculosis, this disease is still widely spread. In some Russian regions the number of patients with tuberculosis is no short of the epidemic level. The long-term use of antibiotics, changes in the composition of the human microbiota and a few other factors have contributed to the emergence of drug-resistant and hypervirulent sublineages of Mycobacterium tuberculosis. Insufficient fundamental knowledge of mechanisms underlying the emergence and evolution of M. tuberculosis clones simultaneously resistant to a wide spectrum of antibiotics and exhibiting increased virulence complicates the situation and necessitates a new strategy to combat the disease. The key concepts of this strategy are «superorganism», «microbiota» and «resistome». The emergence of multidrug-resistant (MDR) and extensively resistant (XDR) strains should be addressed in the context of the «superorganism»; among its components are the human body, its microbiota (specifically, the bacteria that affect the immune status), and M. tuberculosis itself. Clinically studied phenotypes and genotypes of MDR/XDR strains are a result of clonal variability that M. tuberculosis develops as part of this «superorganism». Therefore, it is important to focus on the development of vaccines, adjuvants and probiotics with selective immunomodulating and antioxidant properties.

Keywords: tuberculosis, Mycobacterium tuberculosis, drug resistance, adjuvants, vaccines, cross-drug resistance

КОММЕНТАРИИ (0)